- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03143049
Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma
Randomized Phase 3 Study of Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma. An AMN Study
Study Overview
Detailed Description
In this study, we will prospectively enrol 120 Asian patients with relapsed myeloma after prior treatment with bortezomib and lenalidomide, and randomised them between PCD and PD (60 in each arms). Centers in Singapore, Korea, Taiwan, and Hong Kong will participate in this study.
Pomalidomide is a new immunomodulatory drug, which has been shown to be active in myeloma patients who relapse after bortezomib and lenalidomide. A recent phase III study comparing pomalidomide plus dexamethasone with placebo plus high dose dexamethasone in patients with prior exposure to bortezomib and lenalidomide, showed that the use of pomalidomide significantly improve the overall survival of these patients. In an Asian study, it appears that the addition of cyclophosphamide can induce further response in patients without a response to PD. In the United States, a small randomised phase 2 study of PCD versus PD showed that PCD have a higher response rates, produce deeper response and correspondingly longer progression free survival. Our hypothesis is therefore that PCD will be better than PD and should be the standard pomalidomide containing regimen for relapse myeloma patients. This combination will also be highly relevant to Asian patients because cyclophosphamide is a relatively cheap drug and the combination will be cost effective if proven to be better than PD.
Rationale for the Study Purpose There is a relative lack of data on the efficacy and tolerability of PCD in Asian Patients. The current study will also allow us to test if PCD is better than PD in the treatment of relapse myeloma patients.
Rationale for Study Population The study population will be myeloma patients who have relapsed following prior treatment with bortezomib and lenalidomide. Pomalidomide is the current approved treatment choice for this group of patients and a common indication for us in Asia.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Wee Joo Chng
- Phone Number: 6779 5555
- Email: mdccwj@nus.edu.sg
Study Contact Backup
- Name: Adeline Lin
- Email: adeline_hf_lin@nuhs.edu.sg
Study Locations
-
-
-
Hong Kong, Hong Kong
- Not yet recruiting
- Queen Mary Hospital
-
-
-
-
-
Japan, Japan
- Not yet recruiting
-
-
-
-
-
South Korea, Korea, Republic of
- Not yet recruiting
-
-
-
-
-
Singapore, Singapore
- Recruiting
- National University Hospital
-
-
-
-
-
Taipei, Taiwan
- Not yet recruiting
- National Taiwan University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Multiple myeloma, diagnosed according to standard criteria, with relapsing and refractory disease at study entry
Patients must have evaluable multiple myeloma with at least one of the following (within 21 days of starting treatment)
- Serum M-protein ≥ 0.5g/dL, or
- In subjects without detectable serum M-protein, Urine M-protein ≥ 200mg/24 hour, or serum free light chai (sFLC) > 100mg/L (involved light chain) and an abnormal kappa/Lambda ratio
- Can receive up to 6 lines of prior treatment. (Induction therapy followed by stem cell transplantation and consolidation/maintenance therapy will be considered as one line of treatment)
- Must be relapse refractory to prior lenalidomide and bortezomib. Refractoriness is defined as disease progression on treatment or progression within 6 months after the last dose of a given therapy. Relapse is defined according to the criteria of IMWG
- Males and females ≥ 18 years of age or > country's legal age for adult consent
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2
Patients must meet the following clinical laboratory criteria with 21 days of starting treatment:
- Absolute neutrophil count (ANC) ≥ 1,000/mm3 and platelet ≥ 50,000/mm3 (≥ 30,000/mm3 if myeloma involvement in the bone marrow is >50%)
- Total bilirubin ≤ 1.5 x the upper limit of the normal range (ULN). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN.
- Calculated creatinine clearance ≥ 30mL/min or creatinine < 3mg/dL.
Female patients who:
- Are naturally postmenopausal for at least 2 year before enrolment
- Are surgically sterile
If they are of childbearing potential**, agree to
- adhere to the pomalidomide pregnancy prevention risk management program in Appendix 8 :
- All women of childbearing potential must agree to have two negative pregnancy test within 10-14 days and 24hrs before commencing pomalidomide and use two reliable methods of contraception simultaneously or practice complete abstinence from any heterosexual intercourse during the following time periods related to this study: 1) for at least 28 days before starting study; 2) while participating in the study; 3) dose interruptions; and 4) for at least 28 days after study treatment discontinuation. The two methods of reliable contraception must include one highly effective method and one additional effective method to prevent pregnancy, not plan on conceiving children during or within 6 months following pomalidomide. (See Appendix 8 Pregnancy Prevention and Risk Management Program)
Male patients, even if surgically sterilized (i.e. status post-vasectomy), who:
- Agree to practice effective barrier contraception during the entire study treatment period and through 28 days after the last dose of study treatment, OR
- Agree to completely abstain from heterosexual intercourse, AND
- Must also adhere to the guidelines of the pomalidomide pregnancy prevention and risk management program
Written informed consent in accordance with federal, local and institutional guidelines
- A female of childbearing potential (FCBP) is defined as a sexually mature woman who: 1 has not undergone a hysterectomy or bilateral oophorectomy or 2, has not been naturally post-menopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (I.E, has had menses at any time in the preceding 24 consecutive months).
Exclusion Criteria:
- Female patients who are lactating or pregnant
- Multiple Myeloma of IgM subtype
- Glucocorticoid therapy (prednisolone > 30mg/day or equivalent) within 14 days prior to informed consent obtained
- POEMS syndrome
- Plasma cell leukemia or circulating plasma cells ≥ 2 x 109/L
- Waldenstrom's Macroglobulinaemia
- Patients with known amyloidosis
- Chemotherapy with approved or investigation anticancer therapeutics within 21 days prior to starting pomalidomide treatment
- Focal radiation therapy within 7 days prior to start of pomalidomide. Radiation therapy to an extended field involving a significant volume of bone marrow within 21 days prior to start of pomalidomide
- Immunotherapy (excluding steroids) 21 days prior to start of pomalidomide
- Major surgery (excluding kyphoplasty) within 28 days prior to start of pomalidomide
- Active congestive heart failure (New York Heart Association [NYHA] Class III or IV), symptomatic ischaemia, or conduction abnormalities uncontrolled by conventional intervention. Myocardial infarction within 4 months prior to informed consent obtained
- Known HIV seropositive, hepatitis C infection, and/or hepatitis B (except for patients with hepatitis B surface antigen or core antibody receiving and responding to antiviral therapy directed at hepatitis B: these patients are allowed)
- Patients with known cirrhosis
Second malignancy within the past 3 years except:
- Adequately treated basal cell or squamous cell skin cancer
- Carcinoma in situ of the cervix
- Breast carcinoma in situ with full surgical resection
- Patients with myelodysplastic syndrome
- Patients with steroid or lenalidomide hypersensitivity
- Prior treatment with pomalidomide
- Ongoing graft-versus-host disease
- Patients with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to starting pomalidomide treatment
- Contraindication to any of the required concomitant drugs or supportive treatments
- Any clinically significant medical disease or psychiatric condition that, in the investigator's opinion, may interfere with protocol adherence or a patient's ability to give informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pomalidomide, Cyclophosphamide, Dex (PCD)
|
For PCD, patients will be treated as follows: PO pomalidomide 4mg from D1-21, PO cyclophosphamide 400mg on D1, 8 and 15, and PO or IV dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle. Patients will be assessed every 28 days (+/- 10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first). |
Active Comparator: Pomalidomide, Dex (PD)
|
For PD, Patients will be treated as follows: PO pomalidomide 4mg from D1-21 and PO or IV dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle. Patients will be assessed every 28 days (+/- 10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first). |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival (PFS)
Time Frame: Assessed up to 100 months
|
Defined as the time from commencement of treatment with either PCD or PD to disease progression or death due to any cause, whichever occurs first.
|
Assessed up to 100 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate (ORR)
Time Frame: Assessed up to 100 months
|
Defined as the percentage of patients enrolled that achieve a complete response (CR), or stringent complete response (sCR), or very good partial response (VGPR), or partial response (PR) based on the International Myeloma Working Group criteria anytime from commencement of treatment to the end of study.
|
Assessed up to 100 months
|
Overall survival (OS)
Time Frame: An average of 5 years
|
Defined as the time from commencement of treatment to the date of death
|
An average of 5 years
|
Duration of response (DOR)
Time Frame: Assessed up to 100 months
|
Defined as the time from first evidence of PR or VGPR, or CR, or sCR to confirmation of disease progression or death due to any cause.
|
Assessed up to 100 months
|
Number of Participants affected by Adverse Events
Time Frame: From the time of enrolment into study till 3 years from the date of the last patient randomized
|
Assessed on the basis of the frequency and severity of adverse events
|
From the time of enrolment into study till 3 years from the date of the last patient randomized
|
Collaborators and Investigators
Investigators
- Principal Investigator: Wee Joo Chng, National University Hospital, Singapore
Publications and helpful links
General Publications
- Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schey S, Sonneveld P, Yu X, Sternas L, Jacques C, Zaki M, Dimopoulos M. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013 Oct;14(11):1055-1066. doi: 10.1016/S1470-2045(13)70380-2. Epub 2013 Sep 3.
- Larocca A, Montefusco V, Bringhen S, Rossi D, Crippa C, Mina R, Galli M, Marcatti M, La Verde G, Giuliani N, Magarotto V, Guglielmelli T, Rota-Scalabrini D, Omede P, Santagostino A, Baldi I, Carella AM, Boccadoro M, Corradini P, Palumbo A. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. Blood. 2013 Oct 17;122(16):2799-806. doi: 10.1182/blood-2013-03-488676. Epub 2013 Aug 16.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Disease Attributes
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Recurrence
Other Study ID Numbers
- AMN003
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapse Multiple Myeloma
-
Instituto de Seguridad y Servicios Sociales de...UnknownRefractory Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma ProgressionMexico
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
Memorial Sloan Kettering Cancer CenterRecruitingMultiple Myeloma | Refractory Multiple Myeloma | Relapse Multiple MyelomaUnited States
-
Medical College of WisconsinWithdrawnRefractory Multiple Myeloma | Relapse Multiple Myeloma
-
Dana-Farber Cancer InstituteBristol-Myers SquibbNot yet recruitingMultiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma, RefractoryUnited States
-
Andrew Yee, MDJanssen Research & Development, LLC; AmgenRecruitingMultiple Myeloma | Refractory Multiple Myeloma | Relapse | Multiple Myeloma in RelapseUnited States
-
OncotherapeuticsNot yet recruitingMultiple Myeloma in Relapse | Multiple Myeloma, Refractory
-
Marcela V. Maus, M.D.,Ph.D.RecruitingMultiple Myeloma | Refractory Multiple Myeloma | Multiple Myeloma in RelapseUnited States
-
National Cancer Institute (NCI)CompletedStage II Multiple Myeloma | Stage III Multiple Myeloma | Multiple Myeloma in RelapseUnited States
-
All4CureGlaxoSmithKlineRecruitingMultiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma, RefractoryUnited States
Clinical Trials on PCD
-
NormaTec Industries LPNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)UnknownDiabetic PolyneuropathyUnited States
-
Temple UniversityNutrisystem, Inc.CompletedType 2 DiabetesUnited States
-
Medical University of WarsawCompleted
-
University of Texas Southwestern Medical CenterCompletedIntubation of Pediatric Dental Surgery PatientsUnited States
-
The Cleveland ClinicTerminatedIntubationUnited States
-
Baylor College of MedicineCompletedIntubation; DifficultUnited States
-
International Institute of Rescue Research and...Completed
-
White River Junction Veterans Affairs Medical CenterNormaTec Industries LPUnknownIntermittent ClaudicationUnited States
-
ResMedLymphatic Solutions, LLCCompletedLymphedema | Lymphedema, Secondary | Lymphedema, Lower Limb | Lymphedema of Leg | Lymphedema PrimaryUnited States
-
University of Alabama at BirminghamRecruitingParkinson DiseaseUnited States